Patents by Inventor Avi Ashkenazi

Avi Ashkenazi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-FGFR3 antibodies and methods using same
    Patent number: 11401333
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: August 2, 2022
    Assignee: GENENTECH, INC.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • PYRIMIDINYL-HETEROARYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF USE
    Publication number: 20220048888
    Abstract: Described herein are phenoxy-pyridazinyl-pyrimidine or phenoxy-pyrimidinyl-pyrimidine compounds and pharmaceutically acceptable salts thereof for use in the treatment of Ire1-mediated diseases and cancer.
    Type: Application
    Filed: September 11, 2019
    Publication date: February 17, 2022
    Inventors: Marie-Gabrielle Braun, Paul Gibbons, Wendy Lee, Cuong Q. Ly, Joachim Rudolph, Jacob Bradley Schwarz, Avi Ashkenazi, Ramsay Beveridge, Liang Zhao, Alexandre Lemire, Leo Fu, Kwong Wah Lai, Fei Wang
  • Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders
    Patent number: 10968203
    Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I? structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I? compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 6, 2021
    Assignees: Genentech, Inc., The Regents of the University of California
    Inventors: Marie-Gabrielle Braun, Paul Gibbons, Wendy Lee, Cuong Ly, Joachim Rudolph, Jacob Schwarz, Avi Ashkenazi, Leo Fu, Tommy Lai, Fei Wang, Ramsay Beveridge, Liang Zhao
  • ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME
    Publication number: 20190330355
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: April 10, 2019
    Publication date: October 31, 2019
    Inventors: Avi ASHKENAZI, Jing QING, Christian WIESMANN, Yan WU
  • Anti-FGFR3 antibodies and methods using same
    Patent number: 10287356
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: May 14, 2019
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • Anti-FGFR2/3 antibodies and methods using same
    Patent number: 10208120
    Abstract: The invention provides dual specific anti-FGFR2 and FGFR3 (FGFR2/3) antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: February 19, 2019
    Assignee: GENENTECH, INC.
    Inventors: Yiyuan Yin, Avi Ashkenazi, Paul J. Carter, Mark Chen, Junichiro Sonoda
  • PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS
    Publication number: 20180265497
    Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I? structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I? compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Applicants: Genentech, Inc., The Regents of the University of California
    Inventors: Marie-Gabrielle Braun, Paul Gibbons, Wendy Lee, Cuong Ly, Joachim Rudolph, Jacob Schwarz, Avi Ashkenazi, Leo Fu, Tommy Lai, Fei Wang, Ramsay Beveridge, Liang Zhao
  • Anti-FGFR3 antibodies and methods using same
    Patent number: 10000571
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: June 19, 2018
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • Methods of treating and preventing cancer drug resistance
    Patent number: 9925240
    Abstract: Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using an antagonist of FGFR signaling.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: March 27, 2018
    Assignee: GENENTECH, INC.
    Inventors: Robert L. Yauch, Xiaofen Ye, Avi Ashkenazi
  • ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME
    Publication number: 20170204188
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: November 18, 2016
    Publication date: July 20, 2017
    Inventors: Avi ASHKENAZI, Jing QING, Christian WIESMANN, Yan WU
  • ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME
    Publication number: 20170158769
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: September 15, 2016
    Publication date: June 8, 2017
    Applicant: Genentech, Inc.
    Inventors: Avi ASHKENAZI, Jing QING, Christian WIESMANN, Yan WU
  • TREATMENT OF COMPLEMENT-ASSOCIATED DISORDERS
    Publication number: 20170042967
    Abstract: The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders.
    Type: Application
    Filed: March 9, 2016
    Publication date: February 16, 2017
    Inventors: Avi Ashkenazi, Karim Yussef Helmy, Sherman Fong, Audrey Goddard, Austin L. Gurney, Kenneth James Katschke, Jr., Menno Van Lookeren, William I. Wood
  • Anti-FGFR3 antibodies and methods using same
    Patent number: 9499623
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: November 22, 2016
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • METHODS OF TREATING AND PREVENTING CANCER DRUG RESISTANCE
    Publication number: 20160250287
    Abstract: Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using an antagonist of FGFR signaling.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 1, 2016
    Applicant: Genentech, Inc.
    Inventors: Robert L. YAUCH, Xiaofen YE, Avi ASHKENAZI
  • ANTI-FGFR2/3 ANTIBODIES AND METHODS USING SAME
    Publication number: 20160244525
    Abstract: The invention provides dual specific anti-FGFR2 and FGFR3 (FGFR2/3) antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: November 5, 2015
    Publication date: August 25, 2016
    Applicant: GENENTECH, INC.
    Inventors: Yiyuan YIN, Avi ASHKENAZI, Paul J. CARTER, Mark CHEN, Junichiro SONODA
  • ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME
    Publication number: 20160168250
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: October 19, 2015
    Publication date: June 16, 2016
    Inventors: Avi ASHKENAZI, Jing QING, Christian WIESMANN, Yan WU
  • Methods of using SCD1 antagonists
    Patent number: 9358250
    Abstract: Provided herein are therapies for the treatment of pathological conditions, such as cancer, and method of using SCD1 antagonists.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: June 7, 2016
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Xiangnan Du, Jing Qing
  • Anti-FGFR3 antibodies and methods using same
    Patent number: 9161977
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: October 20, 2015
    Assignee: F. Hoffmann-La Roche AG
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME
    Publication number: 20140187754
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: March 4, 2014
    Publication date: July 3, 2014
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • Anti-FGFR3 antibodies and methods using same
    Patent number: 8710189
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: April 29, 2014
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu